Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Network for Genomic Surveillance in South Africa, Cele, Sandile, COMMIT-KZN Team, Gazy, Inbal, Jackson, Laurelle, Hwa, Shi-Hsia, Tegally, Houriiyah, Lustig, Gila +15 more·2021·Nature
DOI 10.1038/s41586-021-03471-w

Cited by (658)

Items 101–200 of 658

  1. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
    L. Dupont, L. Snell, C. Graham, J. Seow, B. Merrick, T. Lechmere, T. Maguire, Sadie R. Hallett, S. Pickering, T. Charalampous et al. · 2021 · Nature Microbiology
  2. CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants
    Andrew D. Redd, Alessandra Nardin, Hassen Kared, Evan M. Bloch, Andrew S Pekosz, Oliver B Laeyendecker, Brian Abel, Michael Fehlings, Thomas C. Quinn, Aaron A.R. Tobian · 2021 · Open Forum Infectious Diseases
  3. Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta
    Lorenz Ulrich, Nico Joël Halwe, Adriano Taddeo, Nadine Ebert, Jacob Schön, Christelle Devisme, Bettina Salome Trüeb, Bernd Hoffmann, Manon Wider, Xiaoyu Fan et al. · 2021 · Nature
  4. Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes
    Dapeng Sun, Zhe Sang, Yong Joon Kim, Yufei Xiang, Tomer Cohen, Anna K. Belford, Alexis Huet, James F. Conway, Ji Sun, Derek J. Taylor et al. · 2021 · Nature Communications
  5. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
    Aljawharah Alrubayyi, Ester Gea‐Mallorquí, Emma Touizer, Dan Hameiri‐Bowen, Jakub T. Kopycinski, Bethany G. Charlton, Natasha Fisher-Pearson, Luke Muir, Annachiara Rosa, Chloë Roustan et al. · 2021 · Nature Communications
  6. RETRACTED: SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
    Kevin W. Ng, Nikhil Faulkner, Katja Finsterbusch, Mary Wu, Ruth Harvey, Saira Hussain, Maria Greco, Yafei Liu, Svend Kjær, Charles Swanton et al. · 2022 · Science Translational Medicine · Retracted
  7. Covid-19 will become endemic but with decreased potency over time, scientists believe
    Ingrid Torjesen · 2021 · BMJ
  8. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
    Marta Alenquer, Filipe Ferreira, Diana Lousa, Mariana Valério, Mónica Medina-Lopes, Marie‐Louise Bergman, Juliana Gonçalves, Jocelyne Demengeot, Ricardo B. Leite, Jingtao Lilue et al. · 2021 · PLoS Pathogens
  9. Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
    Mary Bushman, Rebecca J. Kahn, Bradford P. Taylor, Marc Lipsitch, William Paul Hanage · 2021 · Cell
  10. SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: A prospective cohort study in keyworkers
    Wyllie, David, Jones, Hayley E, Mulchandani, Ranya, Trickey, Adam, Taylor-Phillips, Sian, Brooks, Tim, Charlett, Andre, Ades, AE, EDSAB-HOME investigators, Moore, Philippa et al. · 2020
  11. Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein
    M. Alejandra Tortorici, Alexandra C. Walls, Anshu Joshi, Young‐Jun Park, Rachel T. Eguia, Marcos C. Miranda, Elizabeth Kepl, Annie M. Dosey, Terry Stevens‐Ayers, Michael J. Boeckh et al. · 2022 · Cell
  12. The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape
    Martin, Darren P, Weaver, Steven, Tegally, Houryiah, San, Emmanuel James, Shank, Stephen D, Wilkinson, Eduan, Lucaci, Alexander G, Giandhari, Jennifer, Naidoo, Sureshnee, Pillay, Yeshnee et al. · 2021
  13. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
    Dennis Lapuente, Thomas Winkler, Matthias Tenbusch · 2023 · Cellular and Molecular Immunology
  14. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status
    Jason A. Neidleman, Xiaoyu Luo, Matthew M. McGregor, Guorui Xie, Victoria Murray, Warner C. Greene, Sulggi A. Lee, Nadia R. Roan · 2021 · eLife
  15. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York
    Anthony P. West, Joel O. Wertheim, Jade C. Wang, Tetyana I. Vasylyeva, Jennifer L. Havens, Moinuddin A. Chowdhury, Edimarlyn Gonzalez, Courtney E. Fang, Steve S. Di Lonardo, Scott Hughes et al. · 2021 · Nature Communications
  16. In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms
    Cankat, S., Demael, M. U., Swadling, L. · 2023 · Cellular & Molecular Immunology
  17. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
    L. Hanke, H. Das, D. Sheward, Laura Perez Vidakovics, E. Urgard, Ainhoa Moliner-Morro, Changil Kim, V. Karl, A. Pankow, Natalie L. Smith et al. · 2022 · Nature Communications
  18. Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications
    Aakriti Dubey, Shweta Choudhary, Pravindra Kumar, Shailly Tomar · 2021 · Current Microbiology
  19. Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France
    Charmet, Tiffany, Schaeffer, Laura, Grant, Rebecca, Galmiche, Simon, Chény, Olivia, Von Platen, Cassandre, Maurizot, Alexandra, Rogoff, Alexandra, Omar, Faïza, David, Christophe et al. · 2021 · The Lancet Regional Health - Europe
  20. Tackling COVID-19 with neutralizing monoclonal antibodies
    Corti, Davide, Purcell, Lisa A., Snell, Gyorgy, Veesler, David · 2021 · Cell
  21. CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern
    Yuanhao Liang, Hongqing Lin, Lirong Zou, Jianhui Zhao, Baisheng Li, Haiying Wang, Jing Lu, Jiufeng Sun, Xingfen Yang, Xiaoling Deng et al. · 2021 · Microbiology Spectrum
  22. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
    Masaharu Shinkai, Kenji Tsushima, Shingo Tanaka, Eri Hagiwara, Norihito Tarumoto, Ichiro Kawada, Yuji Hirai, Sho Fujiwara, Yuko Komase, Takeshi Saraya et al. · 2021 · Infectious Diseases and Therapy
  23. The role of B cells in COVID-19 infection and vaccination
    Shiru Chen, Fei Guan, Fabio Candotti, Kamel Benlagha, Niels Olsen Saraiva Câmara, Andrés A. Herrada, Louisa Katherine James, Jiahui Lei, Heather Miller, Masato Kubo et al. · 2022 · Frontiers in Immunology
  24. Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
    Kenji Maeda, Masayuki Amano, Yukari Uemura, K. Tsuchiya, Tomoko Matsushima, Kenta Noda, Yosuke Shimizu, Asuka Fujiwara, Yuki Takamatsu, Yasuko Ichikawa et al. · 2021 · Scientific Reports
  25. Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination
    Haya Altawalah · 2021 · Vaccines
  26. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity
    Simone I. Richardson, Nelia P. Manamela, Boitumelo M. Motsoeneng, Haajira Kaldine, Frances Ayres, Zanele Makhado, Mathilda Mennen, Sango Skelem, Noleen Williams, Nancy J. Sullivan et al. · 2022 · Cell Reports Medicine
  27. Identification of a therapeutic interfering particle—A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance
    S. Chaturvedi, Gustavo Vasen, M. Pablo, Xinyue Chen, N. Beutler, Arjun J. Kumar, Elizabeth J. Tanner, S. Illouz, Donna Rahgoshay, John C. Burnett et al. · 2021 · Cell
  28. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
    I‐Jung Lee, Cheng‐Pu Sun, Ping‐Yi Wu, Yu-Hua Lan, I-Hsuan Wang, Wen‐Chun Liu, Joyce Pei‐Yi Yuan, Yu-Wei Chang, Sheng-Che Tseng, Szu-I Tsung et al. · 2022 · Journal of Biomedical Science
  29. A global lipid map reveals host dependency factors conserved across SARS-CoV-2 variants
    Scotland E. Farley, Jennifer E Kyle, Hans C. Leier, Lisa Bramer, Jules B. Weinstein, Timothy A. Bates, Joon‐Yong Lee, Thomas Metz, Carsten Schultz, Fikadu Tafesse · 2022 · Nature Communications
  30. The envelope protein of SARS‐CoV‐2 increases intra‐Golgi pH and forms a cation channel that is regulated by pH
    David Cabrera-García, Ramsey Bekdash, Geoffrey Winston Abbott, Masayuki Yazawa, Neil L. Harrison · 2021 · The Journal of Physiology
  31. Characterization and functional interrogation of the SARS-CoV-2 RNA interactome
    Athéna Labeau, Luc Fery-Simonian, Alain Lefèvre‐Utile, Marie Pourcelot, Lucie Bonnet‐Madin, Vassili Soumelis, Vincent Lotteau, Pierre‐Olivier Vidalain, Ali Amara, Laurent Meertens · 2022 · Cell Reports
  32. Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants
    Hang Zhang, Shasha Deng, Liting Ren, Peiyi Zheng, Xiaowen Hu, Tengchuan Jin, Xu Tan · 2021 · Cell Reports
  33. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
    Shiho Tanaka, Gard Nelson, C. Anders Olson, Oleksandr V. Buzko, Wendy Higashide, Annie Shin, Marcos R. Gonzalez, Justin D. Taft, Roosheel S. Patel, Sofija Buta et al. · 2021 · Scientific Reports
  34. SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
    Elizabeth‐Barbara Tatsi, Filippos Filippatos, Athanasios G. Michos · 2021 · Epidemiology and Infection
  35. Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses
    Rory A. Hills, Tiong Kit Tan, Alexander A. Cohen, Jennifer R. Keeffe, Anthony H. Keeble, Priyanthi N.P. Gnanapragasam, Kaya N. Storm, Annie V. Rorick, Anthony P. West, Michelle L. Hill et al. · 2024 · Nature Nanotechnology
  36. ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
    Robert J. Fischer, Neeltje van Doremalen, Danielle R. Adney, Claude Kwe Yinda, Julia Rebecca Port, Myndi G. Holbrook, Jonathan E. Schulz, Brandi N. Williamson, Tina Thomas, Kent Barbian et al. · 2021 · Nature Communications
  37. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
    Michel Obéid, Madeleine Suffiotti, Céline Pellaton, Hasna Bouchaab, Anne Cairoli, Vanja Salvadé, Caroline Stevenel, Rosemary Hottinger, Catherine Pythoud, Lucie Coutechier et al. · 2022 · JAMA Oncology
  38. A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
    Allison J. Greaney, Tyler N. Starr, Rachel T. Eguia, Andrea N. Loes, K. Khan, Farina Karim, S. Cele, J. Bowen, Jennifer K. Logue, D. Corti et al. · 2021 · bioRxiv
  39. SARS-CoV-2’s Variants of Concern: A Brief Characterization
    Aline Miranda Scovino, Elizabeth Chen Dahab, Gustavo Fioravanti Vieira, Leonardo Freire‐de‐Lima, Célio Geraldo Freire-de-Lima, Alexandre Morrot · 2022 · Frontiers in Immunology
  40. Landscape and selection of vaccine epitopes in SARS-CoV-2
    Christof C. Smith, Kelly Shea Olsen, Kaylee M. Gentry, Maria J. Sambade, Wolfgang A. Beck, Jason A. Garness, Sarah Entwistle, Caryn Willis, Steven P. Vensko II, Allison Woods et al. · 2021 · Genome Medicine
  41. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York
    Anthony P. West, Joel O. Wertheim, Jade C. Wang, Tetyana I. Vasylyeva, Jennifer L. Havens, Moinuddin A. Chowdhury, Edimarlyn Gonzalez, Courtney E. Fang, Steve S. Di Lonardo, Scott Hughes et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  42. The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells
    Xiaodong Alan Zhuang, Senko Tsukuda, Florian Wrensch, Peter A. C. Wing, Mirjam Schilling, James M. Harris, Helene Borrmann, Sophie B. Morgan, Jennifer Cane, Laurent Mailly et al. · 2021 · iScience
  43. HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave
    Farina Karim, Inbal Gazy, Sandile Cele, Yenzekile Zungu, Robert Krause, Mallory P. Bernstein, Khadija Khan, Yashica Ganga, Hylton E. Rodel, Ntombifuthi Mthabela et al. · 2021 · eLife
  44. Host Recovery from Respiratory Viral Infection
    Xiaoqin Wei, Harish Narasimhan, Bibo Zhu, Jie Sun · 2023 · Annual Review of Immunology
  45. SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021
    Mandolo, Jonathan, Msefula, Jacquline, Henrion, Marc Y. R., Brown, Comfort, Moyo, Brewster, Samon, Aubrey, Moyo-Gwete, Thandeka, Makhado, Zanele, Ayres, Frances, Motlou, Thopisang et al. · 2021 · BMC Medicine
  46. Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa
    Krishna P. Reddy, Kieran P. Fitzmaurice, Justine A. Scott, Guy Harling, Richard J. Lessells, Christopher Panella, Fatma M. Shebl, Kenneth A. Freedberg, Mark Jacob Siedner · 2021 · Nature Communications
  47. SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021
    Mohammad Alkhatib, Valentina Svicher, Romina Salpini, Francesca Alessandra Ambrosio, Maria Concetta Bellocchi, Luca Carioti, Lorenzo Piermatteo, Rossana Scutari, Giosuè Costa, Anna Artese et al. · 2021 · Microbiology Spectrum
  48. Increased mortality among individuals hospitalised with COVID-19 during the second wave in South Africa
    Waasila Jassat, Caroline Mudara, Lovelyn Ozougwu, Stefano Tempia, Lucille Hellen Blumberg, Mary‐Ann Davies, Yogan G. Pillay, T Carter, Ramphelane Morewane, Milani Wolmarans et al. · 2021 · medRxiv
  49. The ins and outs of SARS-CoV-2 variants of concern (VOCs)
    ‪Mostafa Salehi-Vaziri, Mehdi Fazlalipour, Seyed Mahmood Seyed Khorrami, Kayhan Azadmanesh, Mohammad Hassan Pouriayevali, Tahmineh Jalali, Zabihollah Shoja, Ali Maleki · 2022 · Archives of Virology
  50. Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection
    Ismail Cem Yilmaz, Emre Mert İpekoğlu, Artun Bulbul, Nilsu Turay, Muzaffer Yıldırım, İrem Evcili, Naz Surucu Yilmaz, Nese Guvencli, Yagmur Aydin, Bilgi Gungor et al. · 2021 · Allergy
  51. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses
    Jared E. Feldman, Julia Bals, Clara G. Altomare, Kerri St. Denis, Evan Christopher Lam, Blake Marie Hauser, Larance Ronsard, Maya Sangesland, Thalia Bracamonte Moreno, Vintus Okonkwo et al. · 2021 · Science Immunology
  52. Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants
    Vanessa Monteil, Brett Eaton, Elena N. Postnikova, Michael J. Murphy, Benedict Braunsfeld, Ian Crozier, Franz Kricek, Janine Niederhöfer, Alice Schwarzböck, Helene Breid et al. · 2022 · EMBO Molecular Medicine
  53. An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants
    Wanbo Tai, Shengyong Feng, Benjie Chai, Shuaiyao Lu, Guangyu Zhao, Dong Chen, Wenhai Yu, Liting Ren, Huicheng Shi, Jing Lü et al. · 2023 · Nature Communications
  54. COVID-19 convalescent plasma
    Aaron A.R. Tobian, Claudia S. Cohn, Beth H. Shaz · 2021 · Blood
  55. Rapid replacement of the Beta variant by the Delta variant in South Africa
    Houriiyah Tegally, Eduan Wilkinson, Christian Lorenz Althaus, Marta Giovanetti, James Emmanuel San, Jennifer Giandhari, Sureshnee Pillay, Yeshnee Naidoo, Upasana Ramphal, Nokukhanya Msomi et al. · 2021 · medRxiv
  56. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
    Dong, Jinhui, Zost, Seth J., Greaney, Allison J., Starr, Tyler N., Dingens, Adam S., Chen, Elaine C., Chen, Rita E., Case, James Brett, Sutton, Rachel E., Gilchuk, Pavlo et al. · 2021
  57. Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern
    Robério Amorim de Almeida Pondé · 2022 · Virology
  58. Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine
    Christopher L. D. McMillan, Jovin J. Y. Choo, Adi Idris, Aroon Supramaniam, Naphak Modhiran, Alberto Anastacio Amarilla, Ariel Isaacs, Stacey T. M. Cheung, Benjamin Liang, Helle Bielefeldt‐Ohmann et al. · 2021 · Science Advances
  59. Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
    Fuxing Lou, Maochen Li, Zehan Pang, Lin Jiang, Lin Guan, Lili Tian, Jiaming Hu, Junfen Fan, Huahao Fan · 2021 · Frontiers in Immunology
  60. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains
    Faulkner, Nikhil, Ng, Kevin W, Wu, Mary Y, Harvey, Ruth, Margaritis, Marios, Paraskevopoulou, Stavroula, Houlihan, Catherine, Hussain, Saira, Greco, Maria, Bolland, William et al. · 2021 · eLife
  61. A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease
    Stephanie Patchett, Zongyang Lv, Wioletta Rut, Miklós Békés, Marcin Drąg, Shaun K. Olsen, Tony T. Huang · 2021 · Cell Reports
  62. Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
    Jan‐Stephan Sanders, A. Lianne Messchendorp, Rory D. de Vries, Carla C. Baan, Debbie van Baarle, Rob S. van Binnendijk, Dimitri Adriaan Diavatopoulos, Daryl Geers, Katharina S. Schmitz, Corine H. GeurtsvanKessel et al. · 2022 · Clinical Infectious Diseases
  63. Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
    Richard A. Urbanowicz, Theocharis Tsoleridis, Hannah J. Jackson, Lola Cusin, Joshua D. Duncan, Joseph G. Chappell, Alexander W. Tarr, Jessica Nightingale, Alan R. Norrish, Adeel Ikram et al. · 2021 · Science Translational Medicine
  64. Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies
    Erik Laurini, Domenico Marson, Suzana Aulić, Alice Fermeglia, Sabrina Pricl · 2021 · Scientific Reports
  65. Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics
    Aleksandr V. Kudriavtsev, Anna Vakhrusheva, Valery Nikolaevich Novoseletsky, Marine E. Bozdaganyan, К. В. Шайтан, Mikhail P. Kirpichnikov, Olga S. Sokolova · 2022 · Viruses
  66. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis
    Riikka Nissinen, M Leirisalo-Repo, R Peltomaa, T Palosuo, O Vaarala · 2004 · Annals of the Rheumatic Diseases
  67. The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape
    Darren P Martin, Steven Weaver, Houryiah Tegally, Emmanuel James San, Stephen D. Shank, Eduan Wilkinson, Alexander G. Lucaci, Jennifer Giandhari, Sureshnee Naidoo, Yeshnee Pillay et al. · 2021 · PubMed
  68. CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
    Hoffmann, Donata, Corleis, Björn, Rauch, Susanne, Roth, Nicole, Mühe, Janine, Halwe, Nico Joel, Ulrich, Lorenz, Fricke, Charlie, Schön, Jacob, Kraft, Anna et al. · 2021
  69. COVID-19, the first pandemic in the post-genomic era
    Lucy van Dorp, Charlotte J. Houldcroft, Damien Richard, François Balloux · 2021 · Current Opinion in Virology
  70. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination
    Lin‐Lei Chen, Lu Lu, Charlotte Yee-Ki Choi, Jian‐Piao Cai, Hoi‐Wah Tsoi, Allen Wing‐Ho Chu, Jonathan Daniel Ip, Wan-Mui Chan, Ruiqi Zhang, Xiaojuan Zhang et al. · 2021 · Clinical Infectious Diseases
  71. Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs
    Jesús Horacio Lara Puente, Juan Manuel Carreño, Weina Sun, Alejandro Suárez-Martínez, Luis Alfonso Ramírez-Martínez, Francisco Quezada-Monroy, Georgina Paz-De la Rosa, Rosalía Vigueras-Moreno, Gagandeep Singh, Oscar Rojas-Martínez et al. · 2021 · mBio
  72. SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export
    Ross Hall, Anabel Guedán, Melvyn W. Yap, George R. Young, Ruth Harvey, Jonathan P. Stoye, Kate N. Bishop · 2022 · PLoS Pathogens
  73. Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern
    Scott Wesley Long, Randall J. Olsen, Paul A. Christensen, Sishir Subedi, Robert Olson, James J. Davis, Matthew Ojeda Saavedra, Prasanti Yerramilli, Layne Pruitt, Kristina Reppond et al. · 2021 · American Journal Of Pathology
  74. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses
    Harikrishnan Balachandran, Chansavath Phetsouphanh, David Agapiou, Anurag Adhikari, Chaturaka Rodrigo, Mohamed Hammoud, Lok Bahadur Shrestha, Elizabeth Keoshkerian, Money Gupta, Stuart Grant Turville et al. · 2022 · Cell Reports
  75. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine
    Koichi Furukawa, Lidya Handayani Tjan, Yukiya Kurahashi, Silvia Sutandhio, Mitsuhiro Nishimura, Jun Arii, Yasuko Mori · 2022 · JAMA Network Open
  76. A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron
    Ryota Maeda, Junso Fujita, Yoshinobu Konishi, Yasuhiro Kazuma, Hiroyuki Yamazaki, Itsuki Anzai, Tokiko Watanabe, Keishi Yamaguchi, Kazuki Kasai, Kayoko Nagata et al. · 2022 · Communications Biology
  77. SARS‐CoV‐2 virulence evolution: Avirulence theory, immunity and trade‐offs
    Samuel Alizon, Mircea T. Sofonea · 2021 · Journal of Evolutionary Biology
  78. SARS-CoV-2 Genome Sequencing Methods Differ in Their Abilities To Detect Variants from Low-Viral-Load Samples
    Connie Lam, Karen-Ann Gray, Mailie L. Gall, Rosemarie Sadsad, Alicia Arnott, Jessica C. Johnson-Mackinnon, Winkie Fong, Kerri Basile, Jen Kok, Dominic Edmund Dwyer et al. · 2021 · Journal of Clinical Microbiology
  79. The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?
    Shuxin Guo, Kefang Liu, Jun Zheng · 2021 · International Journal of Biological Sciences
  80. A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virus
    Cai He, H. J. Yang, Xuemei He, Weiqi Hong, Lei Hong, Zimin Chen, Guobo Shen, Li Yang, Jiong Li, Zhenling Wang et al. · 2021 · MedComm
  81. Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein
    Zhuocheng Yao, Lin Zhang, Yuange Duan, Xiaolu Tang, Jian Lü · 2024 · Journal of Infection
  82. The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
    Raquel Pérez-Gómez · 2021 · Journal of Developmental Biology
  83. Nurses' smoking behaviour related to cessation practice.
    Paul F. Slater, Gerard McElwee, Paul J. Fleming, Hugh McKenna · 2006 · PubMed
  84. COVID ‐19 and plasma cells: Is there long‐lived protection?*
    Doan C. Nguyen, Pedro A. Lamothe, Matthew Charles Woodruff, Ankur Singh Saini, Caterina Elisa Faliti, Igñacio Sanz, Frances Eun-Hyung Lee · 2022 · Immunological Reviews
  85. Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation
    Lauren M. Meyers, Andrés H. Gutiérrez, Christine Boyle, Frances E. Terry, Bethany McGonnigal, Andres Μ. Salazar, Michael F. Princiotta, Wiliam D. Martin, Anne Searls De Groot, Leonard Moise · 2021 · npj Vaccines
  86. Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients
    Xiuyuan Lu, Yuki Hosono, Masamichi Nagae, Shigenari Ishizuka, Eri Ishikawa, Daisuke Motooka, Yuki Ozaki, Nicolas Sax, Yuichi Maeda, Yasuhiro Kato et al. · 2021 · The Journal of Experimental Medicine
  87. Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South African Infection Wave
    Jumari Snyman, Shi-Hsia Hwa, Robert G. E. Krause, Daniel Muema, Tarylee Reddy, Yashica Ganga, Farina Karim, Alasdair J. Leslie, Alex Sigal, Thumbi Ndung’u et al. · 2021 · Clinical Infectious Diseases
  88. Evolution of the SARS-CoV-2 genome and emergence of variants of concern
    Iman Safari, Elahe Elahi · 2021 · Archives of Virology
  89. The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
    Fatima Amanat, Mahima Thapa, Tinting Lei, Shaza M. Sayed Ahmed, Daniel C. Adelsberg, Juan Manuel Carreño, Shirin Strohmeier, Aaron J. Schmitz, Sarah Zafar, Julian Q. Zhou et al. · 2021 · medRxiv
  90. SARS-CoV-2 Virus−Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response
    Luís Queirós-Reis, Priscilla Gomes da Silva, José Gonçalves, Andrea Brancale, Marcella Bassetto, João R. Mesquita · 2021 · International Journal of Molecular Sciences
  91. Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)
    Jakob Trimpert, Julia Maria Adler, Kathrin Eschke, Azza Abdelgawad, Theresa C. Firsching, Nadine Ebert, Tran Thi Nhu Thao, Achim Dieter Gruber, Volker Thiel, Nikolaus Osterrieder et al. · 2021 · Science Advances
  92. The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
    Sandrine Mabekou Soh, Yeongjun Kim, Chanwoo Kim, Ui Soon Jang, Hye-Ra Lee · 2021 · The Journal of Microbiology
  93. Real-Time Genomics for Tracking Severe Acute Respiratory Syndrome Coronavirus 2 Border Incursions after Virus Elimination, New Zealand
    Jordan Douglas, Jemma L. Geoghegan, James Hadfield, Remco Bouckaert, Matthew Storey, Xiaoyun Ren, Joep de Ligt, Nigel Peter French, David Welch · 2021 · Emerging infectious diseases
  94. Genomic sequencing of SARS-CoV-2 in Rwanda reveals the importance of incoming travelers on lineage diversity
    Yvan Butera, Enatha Mukantwari, Maria Artesi, Jeanne d’Arc Umuringa, Áine O’Toole, Verity Hill, Stefan Rooke, Samuel Leandro Hong, Simon Dellicour, Onesphore Majyambere et al. · 2021 · Nature Communications
  95. Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern
    Swayam Prakash, Nisha Rajeswari Dhanushkodi, Latifa Zayou, Izabela Coimbra Ibraim, Afshana Quadiri, Pierre-Gregoire A. Coulon, Delia F. Tifrea, Berfin Suzer, Amin Mohammed Shaik, Amruth Chilukuri et al. · 2024 · Frontiers in Immunology
  96. SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
    John Lokman Law, Michael R Logan, Michael Joyce, Abdolamir Landi, Darren J. Hockman, Kevin Crawford, Janelle Johnson, Gerald LaChance, Holly A. Saffran, Justin A. Shields et al. · 2021 · Vaccine
  97. SARS-CoV-2 spike E156G/Δ157-158 mutations contribute to increased infectivity and immune escape
    Tarun Kumar Mishra, Rishikesh Dalavi, Garima Joshi, Atul Kumar, Pankaj Pandey, Sanjeev Shukla, Ram Kumar Mishra, Ajit G. Chande · 2022 · Life Science Alliance
  98. The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State
    Erica Lasek‐Nesselquist, Pascal Lapierre, Erasmus Schneider, Kirsten St. George, Janice D. Pata · 2021 · medRxiv
  99. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
    William R. Strohl, Zhiqiang Ku, Zhiqiang An, Stephen F. Carroll, Bruce A. Keyt, Lila M. Strohl · 2022 · BioDrugs
  100. Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review
    Shilpa Gopinath, Angela Ishak, Naveen Dhawan, Sujan Poudel, Prakriti Singh Shrestha, Prabhjeet Singh, Emily Xie, Peggy Tahir, Sima Marzaban, Jack Michel et al. · 2022 · Tropical Medicine and Infectious Disease